Due to its mechanism of targeting nectin-4, EV is also being investigated for the treatment of other nectin-4-expressing malignancies, including gastrointestinal tumors, small cell lung cancer, and breast cancer (Chatterjee et al., 2021; Challita-Eid et al., 2016). Here, NECTIN4 is linked to breast cancer.